Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
Iterum Therapeutics received a U.S. patent allowance for its sulopenem etzadroxil and probenecid combination, extending protection until 2039. This patent strengthens its portfolio for treating infections, including uncomplicated urinary tract infections, with ongoing Phase 3 trials. Iterum aims to combat multi-drug resistant pathogens globally.
Reference News
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
Iterum Therapeutics received a U.S. patent allowance for its sulopenem etzadroxil and probenecid combination, extending protection until 2039. This patent strengthens its portfolio for treating infections, including uncomplicated urinary tract infections, with ongoing Phase 3 trials. Iterum aims to combat multi-drug resistant pathogens globally.